Clinical Trial for Patients with Relapsed or Refractory DLBCLPosted: March 2, 2011
A Phase I/II study of combination epigenetic therapy with azacitidine and vorinostat in patients with relapsed and refractory DLBCL
Update: this study is closed to enrollment.
Researchers have begun to understand how reversible changes in expression of genes contribute to the development of cancer and allow cancer cells to become resistant to the effects of chemotherapy. These reversible changes are termed “epigenetics” since they do not involve mutations in genes themselves.
In this trial we are studying a combination of 2 drugs that may work by reversing epigenetic changes in patients with diffuse large B-cell lymphoma (DLBCL) that has not responded well to chemotherapy.